Peptide Based Approaches to Type 2 Diabetes Management: GLP1 Analogues
The global burden of type 2 diabetes mellitus (T2DM) continues to escalate, prompting intensive research into novel therapeutic strategies beyond traditional oral hypoglycemics and insulin therapies. Among these, peptide based treatments have emerged as a highly promising avenue, particularly glucagon like peptide 1 (GLP1) analogues, which harness the physiological role of incretin hormones in glycemic […]